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Mechanism of action and potential 
applications of selective inhibition 
of microsomal prostaglandin 
E synthase‑1‑mediated  PGE2 
biosynthesis by sonlicromanol’s 
metabolite KH176m
X. Jiang1,2, H. Renkema1*, B. Pennings1, S. Pecheritsyna1, J. C. Schoeman3, T. Hankemeier3, 
J. Smeitink1,2 & J. Beyrath1
Increased prostaglandin E2  (PGE2) levels were detected in mitochondrial disease patient cells 
harboring nuclear gene mutations in structural subunits of complex I, using a metabolomics screening 
approach. The increased levels of this principal inflammation mediator normalized following exposure 
of KH176m, an active redox‑modulator metabolite of sonlicromanol (KH176). We next demonstrated 
that KH176m selectively inhibited lipopolysaccharide (LPS) or interleukin‑1β (IL‑1β)‑induced  PGE2 
production in control skin fibroblasts. Comparable results were obtained in the mouse macrophage‑
like cell line RAW264.7. KH176m selectively inhibited mPGES‑1 activity, as well as the inflammation‑
induced expression of mPGES‑1. Finally, we showed that the effect of KH176m on mPGES‑1 
expression is due to the inhibition of a  PGE2‑driven positive feedback control‑loop of mPGES‑1 
transcriptional regulation. Based on the results obtained we discuss potential new therapeutic 
applications of KH176m and its clinical stage parent drug candidate sonlicromanol in mitochondrial 
disease and beyond.
Sonlicromanol (also known as KH176), a clinical-stage oral drug candidate, has been developed to combat 
mitochondrial disease. Previously we reported that this active parent compound and its in vivo active metabolite 
KH176m act as potent ROS-redox  modulators1–4.
In order to further characterize the redox pathology in mitochondrial complex I deficient patient-derived 
cells, and examine the effect of our compounds in these cells, we have applied a novel metabolomics-based 
screening method targeted at inflammatory, oxidative and nitrosative stress markers, allowing for the exploration 
of the role of oxidative stress and signaling  lipids5. We found that levels of five interlinked prostaglandins (PG) 
were significantly increased in primary human skin fibroblasts (PHSF) from patients with complex I deficien-
cies, compared with healthy control cells. Interestingly, we also found that KH176m could selectively decrease 
the level of the prostaglandin E2  (PGE2).
PGs are important lipid mediators that sustain physiological and homeostatic functions but can also induce 
pathologic responses such as inflammatory and nociceptive  responses6. Prostaglandins are synthesized from 
arachidonic acid (AA), which is released from the cell membrane by phospholipase A2  (PLA2). Cyclooxygenase 
isoforms 1 and 2 (COX-1 and COX-2) enzymes metabolize AA into prostaglandin G2  (PGG2) and subsequently 
to prostaglandin H2  (PGH2) by bis-oxygenation and peroxidation reactions, respectively.  PGH2 is the common 
precursor of the four principal bioactive prostaglandins  PGD2,  PGI2,  PGE2, and  PGF2α and the prostanoid 
thromboxane A2  (TXA2) that are synthetized by cell- and tissue-specific synthases and isomerases (Fig. 1)7–9.
PG levels are commonly elevated in inflamed tissues and are known to induce and propagate the inflam-
mation  response10. Among the prostanoids,  PGE2 has the greatest impact on the processing of inflammatory 
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pain  signals11.  PGE2 is synthesized from  PGH2 by three different  PGE2 synthases which are either membranous 
(mPGES-1, mPGES-2) or cytosolic (cPGES)  enzymes12. Of these  PGE2 synthases, cPGES and mPGES-2 are con-
stitutively expressed in many organs and tissues, whereas mPGES-1, like COX-2, is up-regulated in response to 
various inflammatory  stimuli13–15.  PGE2 has been shown to enhance the transcriptional expression of mPGES-1 
in combination with inflammatory stimuli revealing a  PGE2-mediated positive feedback control loop of the 
product on its own enzyme. Finally, mPGES-1 has also been shown to be selectively increased in several types 
of cancer and is associated with poor  prognoses7,16,17.
mPGES-1 has recently gained attention as a safer target for anti-inflammatory drugs since it is solely expressed 
in diseased tissue and downstream of the COX enzymes. Though COX enzymes are the current target for most 
commercially available non-steroidal anti-inflammatory drugs (NSAIDs), their inhibition leads to the unspecific 
decrease of major PGs and their use can be limited because of gastric side effects or increased risk of cardiovas-
cular morbidity and mortality.
Based on our screening results, we further investigated the effect of KH176m on  PGE2 biosynthesis in human 
control primary fibroblast cells, as well as in the mouse macrophage-like cell line RAW264.7. Our data indicates 
that KH176m could selectively block the production of  PGE2 induced by the inflammatory stimuli lipopolysac-
charide (LPS) or interleukin-1 beta (IL-1β) in both cell types, without affecting the levels of other prostaglandins. 
We further demonstrated that the inhibitory effect of KH176m on  PGE2 production is dependent on mPGES-1 
inhibition, further blocking mPGES-1 transcriptional expression. Therefore, in addition to be a novel therapeu-
tic option for mitochondrial disease patients, our results indicate that KH176m as well as its parent compound 
sonlicromanol may also potentially be used to treat  PGE2-driven inflammatory consequences such as inflam-
matory pain or cancer.
Figure 1.  Synthesis pathways of prostaglandins and drug targeting strategies. Involved enzymes are indicated 
with oval shapes, PGs and intermediates with boxes.
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Results
KH176m selectively decreases the elevated level of  PGE2 in primary human skin fibroblasts 
from patients with mitochondrial disease. Based on our previous work, sonlicromanol, and its in vivo 
active metabolite KH176m, were both identified as potent ROS-redox modulators. Sonlicromanol is currently in 
clinical development for patients with mitochondrial  disease14. To extend the phenotypical analysis of complex 
I deficient mitochondrial disease (MD) primary fibroblasts, we analyzed these cells and the supernatants with a 
new LC–MS metabolomics-based method for oxidative, nitrosative, and inflammatory  stress5.
As shown in Fig. 2A, three fibroblast cell lines from healthy volunteers (C5120, C5119, and C5118) and three 
fibroblast cell lines from mitochondrial Complex I deficient (MD) patients [S7-5175 (NdufS7, V112M muta-
tion), S2-7277 (NdufS2, R228Q mutation), and V1-5171 (NdufV1, R59X/T423M mutation)] were exposed for 
24 h to 1 µM KH176m or vehicle, after which the cells were processed for metabolomics analysis. We observed 
that five interconnected inflammatory biomarker prostaglandins  (PGA2,  PGE1,  PGE2, 8-iso-PGE1, and 8-iso-
PGE2) were significantly increased in MD fibroblasts, compared with healthy control cells (Fig. 2A). We did 
not detect significant changes in any of the other 40 assessed metabolites (Fig. 2A). Furthermore, our data also 
showed that elevated  PGE1, and  PGE2 levels were significantly decreased by treatment with 1 µM KH176m for 
24 h (Fig. 2A,B).
PGA2 is produced by  PGE2 following rapid non-enzymatic dehydration.  PGE1 is derived from omega 6 fatty 
acids, and acts via the  PGE2 receptor.  PGE1 metabolites play an important role in the balancing act between PG 
groups to manage inflammation, with a primary anti-inflammatory effect on the tissue  microenvironment18. 
The 8-iso-PGE1 is a large scale biosynthetic production of  PGE1 from eicosatrienoic  acid19. The 8-iso-PGE2 is 
produced from arachidonic acid during lipid peroxidation and has been identified as metabolites of  PGE219,20. 
Interestingly, the levels of other prostaglandins, such as  PGD2 and  PGF2α, were not significantly affected by 
mitochondrial disease as well as KH176m exposure (Fig. 2A,B). Using this same panel of fibroblasts we studied 
the expression of the induced enzymes involved in the synthesis of  PGE2 using Western-blot analysis of steady 
state grown cells. COX-2, an enzyme responsible for induced prostaglandin (PG) biosynthesis, was found to be 
below the level of detection, however the mPGES-1 protein levels were increased in 2 out of 3 MD cell lines (up 
to 3.5-fold) (Fig. 2C,D).
We confirmed the effect of KH176m on  PGE2 using an ELISA method, in which fibroblasts were treated with 
increasing concentrations of KH176m for 72 h, and levels of  PGE2 were quantified in the cell supernatant. This 
longer incubation time was required to compensate for the lower sensitivity of the ELISA method. KH176m was 
found to dose-dependently decrease  PGE2 levels, with an  IC50 value of 85.3 ± 17.8 nM (Fig. 3A).
Since  PGE2 synthesis is increased following inflammatory stimuli, we evaluated the effect of KH176m on 
LPS- or IL-1β -induced levels of  PGE2. As a control for selectivity, we also studied changes in  PGD2 production. 
As expected, after 24 h incubation of control fibroblasts with either LPS or IL-1β,  PGE2 and  PGD2 levels in the 
supernatants of the cells were significantly increased (Fig. 3B,C). KH176m treatment efficiently reduced  PGE2 
levels, but not other PGs, with  IC50 92.9 ± 23.5 nM or 0.28 µM, in supernatant of cells treated with LPS (Fig. 3D) 
or IL-1β (Fig. 3E, Supplemental Figure 1A and B), respectively. Of note, in our experimental conditions IL-1β led 
to an approximate four-fold higher increase in  PGE2 production as compared with LPS, which might explain the 
differences in KH176m potencies following the different stimulations. Thus, production of  PGE2, a well-known 
inflammatory mediator, was selectively blocked in the presence of KH176m in human fibroblasts treated with 
inflammatory stimuli.
KH176m selectively and dose‑dependently decreases the level of  PGE2 in RAW264.7 mac‑
rophage‑like cells. LPS is a well-known and powerful macrophage activator. LPS treated RAW264.7 cells 
are a defined model of macrophage activation at the site of  inflammation21. During inflammation, macrophages 
are a central source of  PGE2 production. Therefore, we used an LPS-induced macrophage cell model (RAW264.7) 
to investigate the effect of KH176m on prostaglandin levels. Cells were treated with the inflammatory stimulus 
LPS alone or in combination with increasing concentrations of KH176m. The COX-2 inhibitor celecoxib or 
the COX-1/2 inhibitor indomethacin was used as controls. After 24 h incubation, the culture medium levels 
of  PGE2,  PGD2 and 6-keto-PGF1α (a stable metabolite of  PGI2 commonly measured as a surrogate of  PGI2), 
were quantified by ELISA. As expected, LPS or IL-1β efficiently induced PGs production (Fig. 4A–C, Supple-
mental Figure  1C and D), with KH176m dose-dependently and selectively reducing the level of  PGE2  (IC50 
0.56 ± 0.08 µM), showing no effect on the other two prostaglandins (Fig. 4D, Supplemental Figure 1E). While 
all tested PGs could be reduced in a dose-dependent manner via exposure to the COX inhibitor celecoxib or 
indomethacin (Fig. 4E,F). The specific effect of KH176m on the production of  PGE2 was therefore confirmed in 
this LPS-induced acute inflammation cell model. It was reported that selective inhibition of mPGES-1 may shunt 
its substrate  PGH2 to increase the level other prostaglandins, since COX-2 activity is increased under inflam-
matory  status22. It is important to note that in our experiments, KH176m treatment of RAW264.7 cells did not 
affect  PGD2  levels, or 6-keto-PGF1α production, when  PGE2 levels were decreased (Supplemental Figure 2A). 
KH176i, a redox-inactive form of KH176 which was produced by substituting the hydroxyl function within the 
chromanyl group by a methoxy moiety as expected was unable to reduce  PGE2 level (Supplemental Figure 2B).
KH176m inhibits mPGES‑1 enzyme activity and transcription. Based on the selective control of 
 PGE2 production by KH176m upon inflammatory stimuli, we assessed the effect of KH176m on the activity 
and expression of the mPGES-1 enzyme. RAW264.7 cells were treated with the inflammatory stimulus LPS to 
increase the expression of mPGES-1. After 24 h incubation, microsomes were isolated from the cells and exposed 
to increasing concentrations of KH176m or a single concentration of the previously described mPGES-1 inhibi-
tor PF9184 for 15 min, ex vivo23. mPGES-1 activity was assayed in the microsome fractions by using  PGH2 as a 
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substrate that was converted to  PGE2 and subsequently quantified. The results showed that the mPGES-1 enzy-
matic activity was inhibited in purified microsomes treated with KH176m or the positive control PF9184; the 
IC50 of KH176m was 0.16 ± 0.048 µM (Fig. 5A). Similar results were obtained in primary human control skin 
fibroblasts, and the IC50 of KH176m was 1.51 ± 0.93 µM (Supplemental Figure 3). Furthermore, KH176m had 
no effect on recombinant COX-1 or COX-2 enzymes activity (Fig. 5B).
We investigated the expression of eicosanoid enzymes responsible for the synthesis of  PGE2 in the RAW264.7 
cell model. Cells were treated with the inflammatory stimulus LPS alone or in combination with increasing con-
centrations of KH176m. After 6 or 24 h incubation, mPGES-1, mPGES-2, cPGES, COX-1, and COX-2 RNA and 
protein levels were quantified in cells by qRT-PCR and Western-blot, respectively. As expected, LPS efficiently 
induced the expression of the two inducible enzymes, mPGES-1 and COX-2, at both the protein (Fig. 6A–C) 
and gene (Supplemental Figure 4A and B) levels. Protein (Fig. 6D–F) and mRNA (Supplemental Figure 4C–E) 
levels of the constitutively expressed enzymes mPGES-2, cPGES and COX-1 remained unchanged. Treatment 
with KH176m dose-dependently reduced LPS-induced expression of mPGES-1, but not COX-2, at the protein 
(Fig. 6A–C) and mRNA (Supplemental Figure 4A and B) levels. The constitutive protein and mRNA expression 
levels of mPGES-2, cPGES, and COX-1 remained unchanged after KH176m exposure (Fig. 6A,D–F and Sup-
plemental Figure 4C–E). Taken together, these results showed that KH176m selectively inhibits transcriptional 
expression of mPGES-1 enzyme induced by the inflammatory stimulus LPS, explaining the compound’s selectiv-
ity in reducing  PGE2 levels, but not those of other prostaglandins.
KH176m effect on mPGES‑1 transcriptional regulation is overcome by exogenous addition 
of  PGE2. As a dual effect of KH176m on both the activity and expression of mPGES-1 seemed unlikely, we 
sought a possible mechanism that might reconcile both of these effects. It was previously shown that increased 
synthesis of  PGE2, in combination with an inflammatory stimulus, can enhance the expression of its own enzyme, 
mPGES-124. We therefore hypothesized that KH176m inhibits mPGES-1 activity, reducing  PGE2 production 
and, consequently, blocking the  PGE2-driven positive feedback control of mPGES-1 transcriptional regulation. 
We assessed whether an exogenous addition of  PGE2 could overcome the inhibitory effect of KH176m on LPS- 
or IL-1β-induced mPGES-1 expression. Treatment of primary human skin fibroblasts with increasing concen-
trations of exogenous  PGE2 (1–200 nM) for 24 h revealed a small and dose-dependent (optimum at 100 nM of 
 PGE2) increase of mPGES-1, although this effect was not as pronounced as with IL-1β treatment (Supplemental 
Figure 5A and B). We also measured the expression of mPGES-1 mRNA and protein after 24 h treatment with 
IL-1β in the presence or absence of KH176m and exogenous  PGE2. To further test our hypothesis, we also 
included the known inhibitor of mPGES-1 activity, PF9184. As previously shown, IL-1β-driven increases in 
protein (Fig. 7A,B) and mRNA (Supplemental Figure 5C) expression of mPGES-1 were inhibited by KH176m. 
Interestingly, the same effect was also observed with the mPGES-1-specific inhibitor, PF9184. Under conditions 
of activation by IL-1β and inhibition of mPGES-1 enzyme activity by either KH176m or PF9184, the addition of 
exogenous  PGE2 resulted in the restoration of high mPGES-1 protein (Fig. 7) and mRNA levels (Supplemental 
Figure 4). These results demonstrated that exogenous  PGE2 treatment reversed the effect of KH176m or PF9184 
in IL-1β stimulated fibroblasts, suggesting a positive feedback regulation of the  PGE2 product on the expression 
of its enzyme mPGES-1, which was directly inhibited by either compound (Fig. 7C).
Discussion
Reactive oxygen species (ROS) are the major host defense agents against infection and other  toxins25. Within 
mitochondria, eleven different sites are known to produce superoxide and/or hydrogen peroxide (ROS) by leak-
ing electrons to  oxygen26–28. Mitochondrial Complex I (NADH:ubiquinone oxidoreductase, E.C. 1.6.5.3), when 
deficient like in m.3243A > G MELAS spectrum disorders, is a major source of ROS production and has been 
found to trigger  inflammation29. Mitochondria can therefore act through redox-sensitive inflammatory pathways 
or by direct activation of the inflammasome to modulate innate  immunity30. Previous studies have suggested 
that scavenging of the by-products associated with excessive oxidative stress produced by mitochondria may 
represent a novel therapeutic intervention for inflammation. Increased ROS levels have previously been reported 
in MD patient  cells3,31. Mitochondrial dysfunction leads to mitochondrial ROS production as well as low-grade 
expression of COX-232. The increase in COX-2 expression was accompanied by a dose-dependent increase in 
PGs release. Also increased intracellular ROS can stimulate the production of  PGE2, has been found by Hu 
Figure 2.  KH176m selectively decreases elevated  PGE2 in primary human skin fibroblasts from patients with 
mitochondrial disease. (A) Heat map showing the extracellular levels of oxidative stress related metabolites 
from three healthy control (HC) (C20, C19, C18) and three primary mitochondrial disease cell lines (MD) (S7, 
S2, V1) with complex I deficiency. Cells were analyzed on the oxidative stress platform. Metabolites are plotted 
on x-axis, and the cell lines on the y-axis. The blue color indicates high relative levels, and white indicates 
low relative levels. Heat map is produced with seaborn package (version: 0.11.0) in python (URL: https ://doi.
org/10.5281/zenod o.59284 5)47. (B) Quantitative average of  PGA2,  PGD2,  PGE1,  PGE2, and,  PGF2α in HC or MD 
cells exposed to 1 µM KH176m or vehicle for 24 h is shown. Bar graphs represent the average of 3 independent 
measurements ± SD (n = 9). The comparisons between multiple groups were determined by analysis of variance 
(ANOVA) for parametric data. *p < 0.05; significant difference compared with vehicles. (C) Total protein of three 
HC (C20, C19, C18) and three MD (S7, S2, V1) cell lines with complex I deficiency were extracted and separated 
by SDS-PAGE, and expression of mPGES-1 was analyzed by western blot. (D) Quantification of the western blot 
analysis for mPGES-1. Bar graphs represent the average of at least 3 independent measurements ± SD, and are 
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et al33. Importantly, we now present significant increases in  PGE2 in complex I deficient mitochondrial disease 
cell lines harboring mutations in different nuclear genes encoding structural proteins of NADH:ubiquinone 
oxidoreductase. This was corroborated by increased expression of mPGES-1 in 2/3 patient cell lines. We are cur-
rently exploring a larger panel of mitochondrial disease patient cell lines. Treatment of these fibroblasts with the 
redox-modulating compound KH176m decreased the  PGE2 release from these cells not only in a dose-dependent 
manner but also after activation of  PGE2 production by the bacterial endotoxin LPS or the cytokine IL-1β. This 
effect was  PGE2-specific, since  PGD2 levels, which were also increased in the MD samples, were not decreased 
by exposure to the compound.























































































Figure 3.  KH176m selectively and dose-dependently inhibits  PGE2 induced by inflammatory stimuli LPS or 
IL-1β in primary human skin fibroblasts. (A) Level of  PGE2 was analyzed in the culture medium of fibroblasts 
after treatment with KH176m for 72 h (n = 4). (B) Levels of  PGE2 and  PGD2 were analyzed in the culture 
medium of fibroblasts stimulated with LPS (1 µg/mL) or (C) IL-1β (1 ng/mL) for 24 h. Bar graphs represent 
the average of at least 3 independent measurements ± SD (n = 6–8). (D) Levels of  PGE2 and  PGD2 in the culture 
medium of fibroblasts stimulated with (D) LPS (1 µg/mL) or (E) IL-1β (1 ng/mL) for 24 h alone (set as 100%) 
or in combination with increasing concentrations of KH176m (n = 3). **p < 0.005; ***p < 0.001; significant 
differences compared with vehicles.
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To better understand the role of KH176m in the inflammatory response, we next employed a validated in vitro 
model system for acute inflammation: LPS activation of RAW264.7 macrophage-like mouse cells. Macrophages 
play a critical role in the initiation, maintenance, and resolution of inflammation and they also are a central 
source of  PGE2  production34. Our data showed that levels of  PGE2,  PGD2 and 6-keto-PGF1α were significantly 
increased after LPS stimulation in RAW264.7 cells. Similar to what was observed in human fibroblasts, KH176m 
selectively reduced  PGE2 levels but did not affect the levels of  PGD2 and 6-keto-PGF1α in mouse macrophages. 









































































































Figure 4.  KH176m selectively and dose-dependently decreases the level of  PGE2 induced by LPS in mouse 
macrophage-like cell RAW264.7. Levels of (A)  PGE2, (B)  PGD2, and (C) 6-keto-PGF1α were analyzed in the 
culture medium of RAW264.7 cells stimulated with vehicle or LPS (1 µg/mL) for 24 h. Bar graphs represent 
the average of at least 3 independent measurements ± SD (n = 6–8). Levels of  PGE2,  PGD2, and 6-keto-PGF1α 
in the culture medium of RAW264.7 stimulated with LPS (1 µg/mL) alone or in combination with increasing 
concentrations of KH176m (D), celecoxib (E), or indomethacin (F) (LPS alone set as 100%) (n = 3). ***p < 0.001; 
significant difference compared with vehicles.
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Figure 5.  KH176m decreases the activity of mPGES-1 enzyme. RAW264.7 cells were treated with LPS (1 µg/
mL) for 24 h and microsomes were isolated and used as source of mPGES-1 for ex vivo inhibition experiments. 
(A) The activity of mPGES-1 was measured in microsomes fraction as the conversion of  PGH2 to  PGE2 (n = 6). 
(B) The activity of COX-1 and COX-2 were measured using the COX Inhibitor Screening Kit (n = 3).
Figure 6.  KH176m selectively decreases the expression of mPGES-1 enzyme induced by LPS. RAW264.7 cells 
were treated with various concentrations of KH176m in the presence of LPS (1 µg/mL) for 24 h or 6 h. (A) 
Protein was isolated and separated by SDS-PAGE, and expression of indicated proteins were analyzed by western 
blot. Quantification of the western blot analysis for (B) mPGES-1, (C) COX-2, (D) mPGES-2, (E) cPGES, and 
(F) COX-1. Bar graphs represent the average of at least 3 independent measurements ± SD, and are normalized 
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Figure 7.  Exogenous  PGE2 reversed the effect of KH176m in IL-1β stimulated fibroblasts. Fibroblasts were 
treated with KH176m (3 µM) or PF9184 (3 µM) ±   PGE2 (100 nM) in the presence of IL-1β (1 ng/mL). (A) 
After 24 h, protein was isolated and separated by SDS-PAGE, and expression of indicated proteins were 
analyzed by western blot. (B) Quantification of the western blot analysis. Bar graphs represent the average 
of at least 3 independent measurements ± SD, and are normalized on the vehicle condition. (n = 3) *p < 0.05; 
**p < 0.005; ***p < 0.001; significant differences compared with the marked conditions (a,b,c,d,e). (C) Schematic 
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functions as the terminal enzyme in LPS-induced  PGE2 production. Indeed, we found that KH176m specifically 
inhibited induction of mPGES-1, without affecting the expression of COX-1, COX-2, cPGES, or mPGES-2. The 
inhibition of mPGES-1 was on the mRNA level leading to decreased protein levels although a direct effect on 
translation cannot be excluded.
Our results showed that mPGES-1 enzymatic activity was inhibited by KH176m in a dose-dependent manner, 
in both mouse macrophage-like cells and human fibroblasts. KH176m was found to be more potent in experi-
ments using the rodent cells than human fibroblasts throughout our experiments. However, our studies have 
shown that inhibition of  PGE2 by KH176m is a multifactorial process (involving both protein expression and 
enzyme inhibition). We so far have not studied these processes in enough detail to justify a direct comparison of 
the differ species. Earlier reports have revealed that  PGE2 itself can drive the induction of the enzyme (mPGES-1) 
producing it in a so-called  PGE2-driven positive feedback-loop24. We therefore hypothesized that KH176m is 
not only inhibiting mPGES-1 activity but as a consequence of the reduced  PGE2 synthesis, inhibits its expres-
sion too. Indeed, by adding exogenous  PGE2 to the cells we could counteract the effect of KH176m on mPGES1 
expression, which suggests an indirect effect of KH176m on mPGES-1 expression. Additionally, we revealed that 
a previously known inhibitor of mPGES-1 activity, PF9184, also had an inhibitory effect on mPGES-1 expression. 
This effect was also inhibited by the addition of exogenous  PGE2, which further strengthened our hypothesis.
mPGES-1 is strongly up-regulated by inflammatory stimuli and contributes to the production of pro-inflam-
matory, pro-nociceptive, and proangiogenic  PGE2. Targeting mPGES-1 has recently emerged as a safer alter-
native to current classes of NSAIDs or  Coxibs35,36. Both NSAIDs or Coxibs have been associated with serious 
cardiovascular and gastrointestinal adverse  events37. COX-1 enzyme is constitutively expressed in most tissues 
and has a gastro-protective function, and inhibition of this enzyme can result in gastric damage. Although the 
COX-2 enzyme is mainly expressed in inflamed tissue, COX-2 selective inhibitors have been found to increase 
cardiovascular adverse events and are associated with an increased risk of hypertension. It has been revealed that 
these effects were attributed to the suppression of COX-2-mediated prostacyclin  (PGI2)  synthesis38,39. Indeed, 
 PGI2 has been shown to play an important role in blood vessel dilation and platelet-aggregation inhibition and 
is cardio protective. Contrary to the upstream enzymes COX-1 and COX-2, inhibition of mPGES-1 selectively 
blocks inflammation-induced  PGE2 production, without reducing the synthesis and function of other prosta-
glandins. Targeting mPGES-1 would therefore eliminate the adverse effects associated with the non-selective 
inhibition of prostaglandin synthesis by NSAIDs and Coxibs. mPGES-1 is expressed at low levels in normal 
tissues and upregulated in inflamed tissues and is therefore less prone to on-target adverse effects. Furthermore, 
recent studies have shown that mPGES-1 upregulation is involved in the pathophysiology of several inflamma-
tory neurologic diseases, including Alzheimer’s disease, Parkinson’s disease, and glioma and in several types of 
 cancers7,16,17. Therefore, inhibition of mPGES-1 by KH176m or its parent compound sonlicromanol might be of 
importance as alternative treatment interventions in inflammatory brain diseases and specific cancers.
In recent years, several drug discovery strategies have been employed in the identification of mPGES-1 
inhibitors. The first synthetic mPGES-1 inhibitor was an indole-based carboxylic acid (MK-886), which had been 
earlier reported as a 5-lipoxygenase-activating protein  inhibitor40. Studies also have revealed some endogenous 
fatty acids (arachidonic acid, docosahexaenoic acid) and corresponding eicosanoids such as leukotriene C4, 
 PGJ2 and 15-deoxy-Δ[12,14]-PGJ2 as weak direct mPGES-1  inhibitors41. Currently, a number of diverse natural 
and synthetic compounds have been identified as mPGES-1 inhibitors. However, most of them have exhibited 
drawbacks, including high lipophilicity and interspecies differences, which has hampered preclinical evalua-
tion of efficacy in routine animal models of inflammation. As such, only a handful of these inhibitors (such as 
LY3023703) have entered clinical  trials42–44.
Safety and efficacy of sonlicromanol, the parent compound of KH176m, was evaluated in a phase 1 ran-
domized control trial (RCT) in healthy  volunteers1 and a Phase 2a RCT 4 in patients with mitochondrial 
m.3243A > G spectrum disorder. Of importance, MELAS iPS derived endothelial cells show both pro-atherogenic 
and pro-inflammatory  properties45. Our phase 1 and 2a studies revealed that sonlicromanol had an acceptable 
safety profile and favorable pharmacokinetics, was well tolerated over a treatment period of 28 days, and had 
a positive effect on cognition, an important burden for patients with mitochondrial disease. Interestingly, the 
pharmacokinetics analysis showed a consequent sonlicromanol to KH176m metabolism, with the maximal 
concentration of KH176m in plasma reaching 500  nM1. In the present study we show that KH176m could inhibit 
 PGE2 production with  IC50 ranging between 85 and 500 nM. We also show that  PGE2 was elevated in cells from 
mitochondrial disease patients, it is therefore plausible that the effect of KH176m on  PGE2 production plays a 
role in the overall mechanism of action of sonlicromanol in patients with mitochondrial disease.
In conclusion our findings show that KH176m, a metabolite found in high concentration in human subjects 
dosed with sonlicromanol, selectively inhibits the biosynthesis of  PGE2 via inhibition of mPGES-1. This is of 
particular interest for the treatment of patients with mitochondrial diseases but may also benefit patients with 
other diseases associated with inflammatory pain, inflammatory neurologic diseases and inflammatory cancers.
Methods
Materials. KH176m is a proprietary compound developed by Khondrion (PCT/EP2016/074009)2,3,14. LPS 
from Escherichia coli 0111:B4, IL-1β, glutathione (GSH), iron (II) chloride  (FeCl2), citric acid, indomethacin, and 
celecoxib were obtained from Sigma-Aldrich (Zwijndrecht, The Netherlands).  PGH2 was obtained from Cayman 
Chemical (Hamburg, Germany). PF9184 was obtained from R&D Systems (Abingdon, United Kingdom).
Cell culture. All primary human skin fibroblasts used throughout this study were received from Radbou-
dUMC, Nijmegen, the Netherlands, after obtaining informed consent from donors (Supplemental Table 1). All 
fibroblasts used were established cell lines, so there was no direct involvement of humans and only cell lines were 
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used. The cells were cultured in M199 (Gibco, Landsmeer, The Netherlands) containing 10% fetal bovine serum 
(FBS) (Greiner Bio-one, The Netherlands) and 1% penicillin/streptomycin (P/S) (Corning, Amsterdam, The 
Netherlands). Fibroblasts were passaged by trypsinization every 4–5 days until they reached the passage num-
ber 20, then discarded. The mouse macrophage-like cell line (RAW264.7) was purchased from Sigma-Aldrich 
(Zwijndrecht, The Netherlands). RAW264.7 cells were cultured in DMEM (Gibco, Landsmeer, The Netherlands) 
containing 10% FBS and 1% P/S. The cells were passaged by scraping every 3–4 days until they reached the pas-
sage number 20, and then discarded. All cells were maintained in a humidified atmosphere of 5%  CO2 at 37 °C.
Metabolomics screening. For metabolomics analysis, 150,000 fibroblasts per well were seeded to 6-well 
plates and cultured as described. The next day, cells were treated with KH176m (1 µM) and incubated for 24 h. 
Then, 1 mL culture medium was collected from each well and snap frozen in liquid nitrogen. The cells were 
washed with phosphate buffered saline (PBS) and detached by trypsinization. To quench the cellular metabo-
lism, the plate was put on ice and 1 mL of ice-cold PBS was added to each well. The cell suspension (1,200 µL) 
was transferred to a 1.5 mL Eppendorf tube. Each aliquot was divided into a sample used for protein quanti-
fication (200 µL) and a sample used for metabolomics analyses (1 mL). Both aliquots were centrifuged (340 g, 
5 min, 4 °C) and supernatants were discarded. The cell pellet for protein quantification was snap frozen in liquid 
nitrogen and kept at − 80 °C. The cell pellet for metabolomics analysis was washed by resuspending in 500 µL 
PBS, followed by centrifugation. The cell pellet was snap frozen and kept at − 80 °C.
Samples for metabolomics analysis were extracted using the validated method as described by Schoeman et al., 
with the following starting sample  modifications5. Cell pellets were dissolved in 500 µL of ice cold 80% methanol 
in water (v:v), shaken in a bullet blender (5 min, 22 °C) and centrifuged (253,00 g, 5 min, 4 °C), after which 250 
µL of the supernatant was collected for further analysis. The cell pellet QC pool was prepared by pooling 75 µL 
of the remaining sample volume of each study sample. Prior to metabolomics analyses, cell extracts were dried 
in a speedvac for one hour and reconstituted with 350 µL of the liquid–liquid extraction (LLE) buffer. Culture 
medium samples were prepared by aliquoting 350 µL medium for each study sample whereas the medium QC 
pool was made by pooling 150 µL from the remaining sample volume. The procedure then followed the protocol 
described by Schoeman et al., with samples being spiked with internal standards and antioxidant prior to a two-
fold LLE with butanol:ethyl acetate (1:1, v:v). The organic layers were collected and dried in a speedvac. Dried 
sample extracts were reconstituted and analyzed on the Shimadzu LCMS-8050 (Shimadzu, Japan) consisting of 
an ultra-high-performance LC (UHPLC) system connected to a triple quadrupole mass spectrometer with an ESI 
source. The analytes and ISTDs were measured using multiple reaction monitoring (MRMs) in either positive 
or negative ion mode. The data were normalized to protein concentration.
Prostanoids assay. Cells were seeded at a density of 6000 cells/well (PHSFs) or 15,000 cells/well (RAW264.7) 
into 96-well plates (Greiner Bio-one, Alphen a/d Rijn, The Netherlands). After 24 h, the cells were treated with 
LPS (1 µg/mL) or IL-1β (1 ng/mL) in presence or absence of KH176m at the indicated concentrations and incu-
bation times. Concentrations of  PGE2,  PGD2 and 6-keto-PGF1α in the culture medium were determined using 
enzyme-linked immunosorbent assay (ELISA) kits (Enzo life, Antwerp, Belgium). Samples (100 µL) of culture 
medium were collected from each well and diluted with the assay buffer, if necessary. The concentration of each 
prostanoid was determined according to the instructions provided with the kits and interpolated from standard 
curves. The concentration of each prostanoid was normalized over cell number using the Calcein-AM Viability 
Dye (Thermo Fischer Scientific, Landsmeer, the Netherlands). Briefly, cells were incubated with 2.5 µM Calcein-
AM for 30 min, then washed with DMEM (without phenol red + 10 mM HEPES); fluorescence was acquired on a 
FLUOstar Omega plate reader (excitation 485 nm and emission 520 nm) and analyzed with MARS-Omega data 
analysis software. Incubations with LPS/IL-1β and/or compounds did not systematically affect the cell viabilities.
Measurement of PGES activity. PGES enzyme activities in cell membranes were measured by quantify-
ing the conversion of  PGH2 to  PGE2 using a modified protocol of a previously described  method17. Briefly, cells 
were stimulated with LPS (1 µg/mL) for 24 h, and collected and isolated by sonication (10 s, three times at 1 min 
intervals) in 300 µL ice-cold 1 M Tris–HCl, pH 8.0. After centrifugation at 15,000 g for 10 min at 4 °C, the super-
natant was collected and the microsomal membrane fraction was pelleted by further centrifugation a 100,000 g 
for 1 h at 4 °C. The pellets were resuspended in 100 µL 0.1 M Tris–HCl, pH 8.0, containing protease inhibitors 
(cOmplete ULTRA Tablets, Mini, EDTA-free, EASYpack Protease Inhibitor Cocktail, from Roche, Woerden, The 
Netherlands), and were used as enzyme source to measure PGES activity.
Briefly, the protein content of the microsomal membrane fractions was quantified using a Bradford assay. For 
each incubation, the volume corresponding to 90 µg of total protein was mixed with test compounds (KH176m 
or PF9184) in 0.1 M Tris–HCl, pH 8.0 containing 2.5 mM GSH and 14 µM indomethacin in a final volume of 120 
μL and incubated for 15 min at room temperature to allow interaction with mPGES-1. Activity measurements 
were initiated by the addition of  PGH2 (2 µg). After incubation on ice for 60 s, the reaction was stopped by via 
40 mM  FeCl2 solution containing 80 mM citric acid in  PGE2 ELISA assay buffer. The  PGE2 concentrations in the 
samples were subsequently quantified using a  PGE2 ELISA kit as described above.
COX enzymatic activity‑cell free assay. The activity of KH176m on COX-1 and COX-2 was deter-
mined using COX Inhibitor Screening Kit (Bio-Vision, Huissen, The Netherlands) following the manufacturer’s 
instructions.
Western blot analysis. Cells were lysed in buffer (50 mM Tris–HCl pH8.0, 150 mM NaCl, 0.2% Triton 
X100, containing 0.1 mg/mL DNAse (Sigma-Aldrich, Zwijndrecht, The Netherlands) with protease inhibitor 
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(cOmplete ULTRA Tablets, Mini, EDTA-free, EASYpack Protease Inhibitor Cocktail) and PhosStop (Phosphatase 
inhibitor) from Roche (Woerden, The Netherlands). Total proteins (45 µg) were separated by 10% or 12% sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene difluoride 
(PVDF) membrane (Merck Millipore, Amsterdam, The Netherlands). Membranes were blocked with 5% BSA 
in TBST (Tris Buffered Saline with 0.1% Tween 20) for 1 h at room temperature and then incubated overnight 
with primary antibodies at 4 °C (primary antibodies are listed in Supplemental Table 2). Corresponding second-
ary antibodies (Goat anti Mouse IRDye 680 or Goat anti Rabbit IRDye 800, 1:10,000, Odyssey, Leusden, The 
Netherlands) were used to detect the primary antibodies. Finally, membranes were scanned and analyzed on the 
Odyssey CLx Infrared Imaging System (LI-COR, Lincoln, The United States).
RNA extraction and qRT‑PCR. Total RNA was isolated from cells using the TRIzol reagent (Invitrogen, 
Uden, The Netherlands). The obtained mRNA was reverse-transcribed to cDNA from 2 µg of total RNA using a 
FirstStrand cDNA Synthesis Kit (Roche, Woerden, The Netherlands). Quantitative PCR analysis was performed 
in a total volume of 20 µL containing cDNA template, sense and antisense primers, and SYBR Green mas-
ter mix (QIAGEN, Venlo, The Netherlands). Data was expressed as fold changes relative to control conditions 
(unstimulated cells) normalized to housekeeping gene PPIA using the ∆∆CT  method46. Each PCR was performed 
in duplicate at two different time points during three independent experiments (primer information is shown 
in Supplemental Table 3).
Statistical assay. Unless otherwise indicated, all experiments were performed with three independent bio-
logical repeats with each three technical repeats. The results were presented as mean ± S.D. Statistical analysis 
was performed with GraphPad Prism (GraphPad Prism 7.0 Software). Experiments were designed to compare 
multiple groups were determined by analysis of variance (ANOVA). Experiments were designed to determine 
whether the effects of stress were dependent on vehicle conditions. Variance between the experimental groups 
was determined by Student t-test. p < 0.05 was considered statistically significant. Information about the number 
of samples (n) is included in the figures and figure legends.
Data availability
The data that support the finding of this study are available on the request from the corresponding author [H.R.].
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